1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

  • March 2015
  • 62 pages
  • La Merie Publishing
Report ID: 2841933

Summary

Table of Contents

Search Inside

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2014 sales of over US$ 6.9 bln). The commercial attractiveness of rituximab has stimulated companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in less regulated countries, but also in phase III studies in Western regulated markets.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

  • $ 4995
  • Industry report
  • June 2017
  • by GBI Research

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Summary Oncology comprises a large and diverse group of indications, encompassing ...

Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market

  • $ 4995
  • Industry report
  • June 2017
  • by GBI Research

Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market Summary Asthma is a common chronic inflammatory disease of the ...

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • Industry report
  • July 2017
  • by GBI Research

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Colorectal cancer (CRC) originates in eithe ...

Global Biosimilars Market

July 2017 $ 4250

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Europe - Forecast

  • August 2017
    9 pages
  • Therapy  

    Hospital  

  • Europe  

View report >

Targeted Therapy Market in the US - Forecast

  • August 2017
    8 pages
  • Targeted Therap...  

    Oncology  

  • United States  

View report >

Global Therapy Market and Breast Cancer Statistics

  • August 2017
    169 pages
  • Therapy  

    Breast Cancer  

    Cancer  

  • Asia  

    World  

    United States  

View report >

Therapy Market

21 days ago

Related Market Segments :

Monoclonal Antibody
Biosimilar
Lymphoma

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.